We randomized 2,185 patients with type 2 diabetes mellitus ( T2DM ) and stage 4 chronic kidney disease ( CKD ) ( estimated glomerular filtration rate 15 to < 30 mL min ( -1 ) 1.73 m ( -2 ) ) to once-daily bardoxolone methyl ( 20 mg ) or placebo .